Milena Cioana

Milena Cioana

Auto-generated profile, based on publicly available information

Milena Cioana

Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2020 in Autism Research
Verified
Journal Article
Closed access
PDF file
MCMilena Cioana
Milena Cioana
BMBernadeta Michalski
Bernadeta Michalski
MFMargaret Fahnestock
Margaret Fahnestock

1 September 2024 in Retina
Verified
Journal Article
Closed access
MCMilena Bhsc Cioana
Milena Bhsc Cioana
SNSumana Naidu
Sumana Naidu
PFParsa M. Far
Parsa M. Far
SYShanna C. Yeung
Shanna C. Yeung
YYYuyi Mbbs You
Yuyi Mbbs You
PYPeng Yan
Peng Yan
Purpose: To compare visual outcomes of endophthalmitis following intravitreal injections (IVIs) and cataract extraction by causative organism. Methods: Searches in Cochrane Central Register of Controlled Trials, MEDLINE, and Embase identified articles reporting visual outcomes by causative organisms in post-IVI and cataract extraction endophthalmitis cases from January 2010 to February 2022. A random-effects meta-analysis compared visual improvement among endophthalmitis cases caused by causative organisms. Results: Eighty-five out of 3,317 retrieved studies were included. The highest degree of visual acuity improvement in both post-IVI and postcataract extraction endophthalmitis was seen in cases caused by coagulase-negative staphylococci, followed by gram-negative organisms and other gram-positive organisms such as streptococci and enterococci. Culture-negative cases showed more visual acuity improvement than culture-positive cases in post-IVI endophthalmitis. These results remained consistent when accounting for endophthalmitis treatment, IVI type, condition requiring IVI treatment, follow-up period, and initial preprocedural visual acuity. Conclusion: Coagulase-negative staphylococci and gram-negative organisms show the most visual acuity improvement in both post-IVI and postcataract extraction endophthalmitis. Other gram-positive organisms such as streptococci and enterococci are associated with less visual improvement. This updated systematic review and meta-analysis revealed that the results of the Endophthalmitis Vitrectomy Study are consistent decades later despite advancements in surgical practices and the evolution of microorganisms over time.

14 April 2023 in Canadian Journal of Ophthalmology
Verified
Journal Article
Closed access
PDF file
MCMilena Cioana
Milena Cioana
RGRishi B. Gupta
Rishi B. Gupta
ETEric S. Tam
Eric S. Tam
HCHannah H. Chiu
Hannah H. Chiu
IGIleana Gold
Ileana Gold
SSSohel Somani
Sohel Somani

1 February 2024 in Journal of Cataract & Refractive Surgery
Verified
Journal Article
Closed access
MCMilena Bhsc Cioana
Milena Bhsc Cioana
YPYogesh Md Frcsc Patodia
Yogesh Md Frcsc Patodia
LTLili Md Frcsc Tong
Lili Md Frcsc Tong
HCHannah H. Md Frcsc Chiu
Hannah H. Md Frcsc Chiu
ETEric S. Md Frcsc Tam
Eric S. Md Frcsc Tam
SSSohel Md Frcsc Somani
Sohel Md Frcsc Somani
Purpose: To evaluate the effect of femtosecond laser-assisted cataract surgery (FLACS) and manual cataract surgery (MCS) on proinflammatory cytokine expression in patients with diabetes vs nondiabetic patients. Setting: Outpatient surgical center in Vaughan, Ontario, Canada. Design: Prospective cohort study. Methods: Patients with diabetes and nondiabetic patients undergoing noncomplicated MCS or FLACS were assigned into 4 cohorts: MCS nondiabetic (n = 30), FLACS nondiabetic (n = 42), MCS diabetic (n = 40), and FLACS diabetic (n = 40). Aqueous humor inflammatory mediator concentrations were evaluated at MCS onset and after femtosecond laser treatment. The presence of cystoid macular edema, anterior chamber (AC) inflammation, central retinal thickness, macular volume, and retinal microvascular changes (through optical coherence tomography angiography) were evaluated preoperatively and on postoperative day 1, week 1, month 1 (POM1), and month 3 (POM3). Results: Patients with diabetes receiving FLACS had a higher concentration of interleukin (IL)-7, IL-13, and interferon-induced protein-10 than MCS diabetic patients; they also demonstrated higher levels of vascular endothelial growth factor and lower levels of interferon (IFN)-γ, granulocyte colony-stimulating factor, and IFN-α2 compared with MCS nondiabetic patients. Macular volume appeared to be significantly higher in MCS diabetic vs MCS non-diabetic patients at POM1 and between FLACS diabetic vs FLACS nondiabetic patients at POM3. There were no other significant differences between the cohorts for any parameter. Conclusions: FLACS use in patients with diabetes demonstrated some differences in AC cytokine expression compared with non-diabetic FLACS or diabetic patients undergoing MCS; however, there was no increase in clinical inflammatory biomarkers. FLACS seems to be a safe technique to use in patients with diabetes.

1 January 2019 in Adolescent Health, Medicine and Therapeutics
Verified
Journal Article
Open access
PDF file
MCMilena Cioana
Milena Cioana
DPDevin Peterson
Devin Peterson
PMPaul Missiuna
Paul Missiuna
RERon El-Hawary
Ron El-Hawary
TCTimothy Carey
Timothy Carey
MSM. Constantine Samaan
M. Constantine Samaan
In this report, we document the discussions and recommendations of a national conference designed to create a coalition to tackle adolescent idiopathic scoliosis (AIS) held on June 6 and 7, 2017 in Hamilton, ON, Canada. The goal of the establishment of this coalition is to join the efforts of patients, parents, physicians, researchers and other stakeholders to identify stakeholders' perspectives and to categorize gaps in knowledge and target further AIS research and clinical care priorities. The participants' main priorities included focus on shared decision making regarding clinical and research priorities between the stakeholders on the clinical, research and policy sides with patients and families. In addition, improvements in the dissemination of information via digital platforms and identification of cost-effective screening strategies that may help early identification and intervention were also recognized as a priority. Commitment was reached to form a national coalition to understand the determinants of this condition and enhance patient outcomes through improved clinical care and research efforts.

21 April 2025 in Canadian Journal of Ophthalmology
Verified
Journal Article
Open access
MIMariam Issa
Mariam Issa
MCMilena Cioana
Milena Cioana
MPMarko M. Popovic
Marko M. Popovic
LDLaura Donaldson
Laura Donaldson
JMJonathan Micieli
Jonathan Micieli
EMEdward Margolin
Edward Margolin
To determine the potential for morbidity and mortality in patients referred to a tertiary neuro-ophthalmology service for evaluation of diplopia. A retrospective chart review of all patients seen by to a tertiary neuro-ophthalmologists in a tertiary neuro-ophthalmology practice between December 2, 2021, and May 21, 2022, was performed. All patients who were referred for diplopia were included. The primary outcome was to describe the potential for vision loss, progression of symptoms, or systemic morbidity or mortality without a neuro-ophthalmic consult. One hundred ninety-six patients were referred for diplopia. The mean age at presentation was 61.3 ± 17.0 years, and 48.5% were women. The most common final diagnosis reached following neuro-ophthalmology consultation were cranial nerve palsies (38.3%, 75/196), convergence insufficiency and decompensated phoria (22.4%, 44/196), non-neuro-ophthalmic causes (19.9%, 39/196), thyroid eye disease (4.5%, 9/196), myasthenia gravis (3.5%, 7/196), and multiple sclerosis (6/196, 3.1%). On the basis of final diagnosis, 15.3% of patients referred to the neuro-ophthalmology service for diplopia had the potential for morbidity or mortality. Specifically, 1% (2/196) were at risk for visual loss due severe papilledema in the context of untreated idiopathic intracranial hypertension, and 3.0% (6/196) had the potential for systemic morbidity or mortality due to their final diagnosis (brain aneurysms in 2/196, pituitary apoplexy in 1/196, anaplastic glioma in 1/196, and other malignancy in 2/196). In addition, 11.2% (22/196) had the potential for progression of symptoms and systemic morbidity due to thyroid eye disease (9/196), myasthenia gravis (7/196), and multiple sclerosis (6/196). Of the patients who had a prereferral neuroimaging study, 30.1% required additional neuroimaging after neuro-ophthalmic consultation. Overall, 15.3% (30/196) of patients with diplopia had potential for morbidity and mortality without neuro-ophthalmic consultation. This study emphasizes the importance of urgent neuro-ophthalmologic referral for patients with diplopia to allow for appropriate evaluation and investigations to reduce potential morbidity and mortality.